Relevant bibliographies by topics / Prostaglandins Therapeutic use

Academic literature on the topic 'Prostaglandins Therapeutic use'

Author: Grafiati
Published: 10 December 2022
Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Prostaglandins Therapeutic use.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Prostaglandins Therapeutic use"

1

Jara-Gutiérrez, Álvaro, and Victoriano Baladrón. "The Role of Prostaglandins in Different Types of Cancer." Cells 10, no. 6 (June 13, 2021): 1487. http://dx.doi.org/10.3390/cells10061487.

Full text
Abstract:
The prostaglandins constitute a family of lipids of 20 carbon atoms that derive from polyunsaturated fatty acids such as arachidonic acid. Traditionally, prostaglandins have been linked to inflammation, female reproductive cycle, vasodilation, or bronchodilator/bronchoconstriction. Recent studies have highlighted the involvement of these lipids in cancer. In this review, existing information on the prostaglandins associated with different types of cancer and the advances related to the potential use of them in neoplasm therapies have been analyzed. We can conclude that the effect of prostaglandins depends on multiple factors, such as the target tissue, their plasma concentration, and the prostaglandin subtype, among others. Prostaglandin D2 (PGD2) seems to hinder tumor progression, while prostaglandin E2 (PGE2) and prostaglandin F2 alpha (PGF2α) seem to provide greater tumor progression and aggressiveness. However, more studies are needed to determine the role of prostaglandin I2 (PGI2) and prostaglandin J2 (PGJ2) in cancer due to the conflicting data obtained. On the other hand, the use of different NSAIDs (non-steroidal anti-inflammatory drugs), especially those selective of COX-2 (cyclooxygenase 2), could have a crucial role in the fight against different neoplasms, either as prophylaxis or as an adjuvant treatment. In addition, multiple targets, related to the action of prostaglandins on the intracellular signaling pathways that are involved in cancer, have been discovered. Thus, in depth research about the prostaglandins involved in different cancer and the different targets modulated by them, as well as their role in the tumor microenvironment and the immune response, is necessary to obtain better therapeutic tools to fight cancer.
APA, Harvard, Vancouver, ISO, and other styles
2

Calder, AA. "Prostaglandins as therapy for labour induction or therapeutic abortion." Reproduction, Fertility and Development 2, no. 5 (1990): 553. http://dx.doi.org/10.1071/rd9900553.

Full text
Abstract:
(a) Prostaglandins (especially PGE2) are highly effective for ripening the cervix and inducing labour. If the cervix is already ripe, a small dose of PGE2 may be all that is required to initiate a labour which resembles spontaneous labour as closely as possible. (b) Amniotomy is the central event. Although it is possible for an infant to be born in the caul, i.e. in intact membranes, it is the general rule for the membranes to rupture or to be ruptured during labour. Such rupture leads to heightened activity of endogenous prostaglandins. The timing of amniotomy is crucial. Performed too early, before the cervix is ripe, it may lead to complications. Delayed too late, we may lose the advantage of its uterine sensitizing. (c) Oxytocin is a potent myometrial stimulant if the uterus is primed to respond to it by prostaglandins, either endogenous or exogenous. It must be given intravenously and many mothers find this disagreeable. In most instances of labour induction, a proper combination of prostaglandin therapy and amniotomy may allow the use of oxytocin to be avoided, but it remains the therapy of final resort to carry labour through to delivery if required.
APA, Harvard, Vancouver, ISO, and other styles
3

Toris, Carol B., and Vikas Gulati. "The biology, pathology and therapeutic use of prostaglandins in the eye." Clinical Lipidology 6, no. 5 (October 2011): 577–91. http://dx.doi.org/10.2217/clp.11.42.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ragel, Brian T., Randy L. Jensen, and William T. Couldwell. "Inflammatory response and meningioma tumorigenesis and the effect of cyclooxygenase-2 inhibitors." Neurosurgical Focus 23, no. 4 (October 2007): E7. http://dx.doi.org/10.3171/foc-07/10/e7.

Full text
Abstract:
✓In this article the authors discuss the rationale and research supporting the hypothesis that meningioma tumorigenesis may, in part, be driven by overexpression of cyclooxygenase-2 (Cox-2) and that treatment with celecoxib, a selective Cox-2 inhibitor, may hold therapeutic promise. Because therapies for recurrent or aggressive meningiomas (atypical or malignant subtypes) such as chemotherapy and radiotherapy generally offer little therapeutic benefit, interest in targeting Cox-2 has grown. This rate-limiting enzyme of prostaglandin synthesis can be inhibited with nonsteroidal antiinflammatory drugs (NSAIDs) such as ibuprofen and celecoxib. Treatment with NSAIDs has been shown to curb the tumorigenic properties of prostaglandins in several cancer models via both Cox-2-dependent and -independent mechanisms. In addition, celecoxib is well tolerated in humans, making its use as a chronic therapy for meningiomas attractive.
APA, Harvard, Vancouver, ISO, and other styles
5

Fattahi, Mohammad Javad, and Abbas Mirshafiey. "Prostaglandins and Rheumatoid Arthritis." Arthritis 2012 (November 7, 2012): 1–7. http://dx.doi.org/10.1155/2012/239310.

Full text
Abstract:
Rheumatoid arthritis (RA) is a chronic, autoimmune, and complex inflammatory disease leading to bone and cartilage destruction, whose cause remains obscure. Accumulation of genetic susceptibility, environmental factors, and dysregulated immune responses are necessary for mounting this self-reacting disease. Inflamed joints are infiltrated by a heterogeneous population of cellular and soluble mediators of the immune system, such as T cells, B cells, macrophages, cytokines, and prostaglandins (PGs). Prostaglandins are lipid inflammatory mediators derived from the arachidonic acid by multienzymatic reactions. They both sustain homeostatic mechanisms and mediate pathogenic processes, including the inflammatory reaction. They play both beneficial and harmful roles during inflammation, according to their site of action and the etiology of the inflammatory response. With respect to the role of PGs in inflammation, they can be effective mediators in the pathophysiology of RA. Thus the use of agonists or antagonists of PG receptors may be considered as a new therapeutic protocol in RA. In this paper, we try to elucidate the role of PGs in the immunopathology of RA.
APA, Harvard, Vancouver, ISO, and other styles
6

Al-Waili, Noori, Khelod Salom, and Ahmad A. Al-Ghamdi. "Honey for Wound Healing, Ulcers, and Burns; Data Supporting Its Use in Clinical Practice." Scientific World JOURNAL 11 (2011): 766–87. http://dx.doi.org/10.1100/tsw.2011.78.

Full text
Abstract:
The widespread existence of unhealed wounds, ulcers, and burns has a great impact on public health and economy. Many interventions, including new medications and technologies, are being used to help achieve significant wound healing and to eliminate infections. Therefore, to find an intervention that has both therapeutic effect on the healing process and the ability to kill microbes is of great value. Honey is a natural product that has been recently introduced in modern medical practice. Honey's antibacterial properties and its effects on wound healing have been thoroughly investigated. Laboratory studies and clinical trials have shown that honey is an effective broad-spectrum antibacterial agent. This paper reviews data that support the effectiveness of natural honey in wound healing and its ability to sterilize infected wounds. Studies on the therapeutic effects of honey collected in different geographical areas on skin wounds, skin and gastric ulcers, and burns are reviewed and mechanisms of action are discussed. (Ulcers and burns are included as an example of challenging wounds.) The data show that the wound healing properties of honey include stimulation of tissue growth, enhanced epithelialization, and minimized scar formation. These effects are ascribed to honey's acidity, hydrogen peroxide content, osmotic effect, nutritional and antioxidant contents, stimulation of immunity, and to unidentified compounds. Prostaglandins and nitric oxide play a major role in inflammation, microbial killing, and the healing process. Honey was found to lower prostaglandin levels and elevate nitric oxide end products. These properties might help to explain some biological and therapeutic properties of honey, particularly as an antibacterial agent or wound healer. The data presented here demonstrate that honeys from different geographical areas have considerable therapeutic effects on chronic wounds, ulcers, and burns. The results encourage the use of honey in clinical practice as a natural and safe wound healer.
APA, Harvard, Vancouver, ISO, and other styles
7

Jarocka-Karpowicz, Iwona, and Agnieszka Markowska. "Therapeutic Potential of Jasmonic Acid and Its Derivatives." International Journal of Molecular Sciences 22, no. 16 (August 5, 2021): 8437. http://dx.doi.org/10.3390/ijms22168437.

Full text
Abstract:
A modern method of therapeutic use of natural compounds that would protect the body are jasmonates. The main representatives of jasmonate compounds include jasmonic acid and its derivatives, mainly methyl jasmonate. Extracts from plants rich in jasmonic compounds show a broad spectrum of activity, i.e., anti-cancer, anti-inflammatory and cosmetic. Studies of the biological activity of jasmonic acid and its derivatives in mammals are based on their structural similarity to prostaglandins and the compounds can be used as natural therapeutics for inflammation. Jasmonates also constitute a potential group of anti-cancer drugs that can be used alone or in combination with other known chemotherapeutic agents. Moreover, due to their ability to stimulate exfoliation of the epidermis, remove discoloration, regulate the function of the sebaceous glands and reduce the visible signs of aging, they are considered for possible use in cosmetics and dermatology. The paper presents a review of literature data on the biological activity of jasmonates that may be helpful in treatment and prevention.
APA, Harvard, Vancouver, ISO, and other styles
8

Breyer, M. D., H. R. Jacobson, and R. M. Breyer. "Functional and molecular aspects of renal prostaglandin receptors." Journal of the American Society of Nephrology 7, no. 1 (January 1996): 8–17. http://dx.doi.org/10.1681/asn.v718.

Full text
Abstract:
The diverse intrarenal effects of the prostaglandins (PG) are mediated by distinct guanine nucleotide regulatory protein (G-protein)-coupled receptors. The cDNA for these receptors have been cloned, their signal transduction mechanisms determined, and their intrarenal distribution mapped. PGE2, the major intrarenal prostaglandin, interacts with at least three distinct E-prostanoid (EP) receptors that are highly expressed in specific regions of the kidney. Each EP receptor not only selectively binds PGE2, but also preferentially couples to different signal transduction pathways, including: stimulation of cAMP generation, via Gq (EP2 and EP4 receptors); inhibition of cAMP generation, via Gi (EP3 receptors); and activation of phosphatidylinositol hydrolysis (EP1 receptor), via one of the Gq family members. Activation of each these EP receptors is responsible for a distinct renal effect of PGE2, including its well-described renal hemodynamic and transport effects along the nephron. Other intrarenal prostanoid receptors include the PGF2 alpha receptor (FP), the thromboxane A2 receptor (TP) and the prostacyclin receptor (IP). Knowledge about localization of these receptors and their affinities for receptor-selective agonists and antagonists should aid in the understanding of renal disease and the development of therapeutic strategies for the use of these prostaglandin analogs in select renal diseases.
APA, Harvard, Vancouver, ISO, and other styles
9

Mistry, C. D., C. J. Lote, R. Gokal, W. J. C. Currie, M. Vandenburg, and N. P. Mallick. "Effects of sulindac on renal function and prostaglandin synthesis in patients with moderate chronic renal insufficiency." Clinical Science 70, no. 5 (May 1, 1986): 501–5. http://dx.doi.org/10.1042/cs0700501.

Full text
Abstract:
1. The renal effects of therapeutic doses of sulindac were studied in nine patients with stable renal insufficiency, mean creatinine clearance 37.0 ± 2.2 ml min−1 1.73 m−2 (range 24.7–54.6 ml min−1 1.73 m−2). 2. Nine days' treatment with sulindac produced a small, but significant, reduction in the mean creatinine clearance (37.0 ± 2.2 to 34.7 ± 2.2 ml min−1 1.73 m−2; P < 0.02) and 99mTc diethylenetriaminepenta-acetate (DTPA) clearance (35.5 ± 3.4 to 31.4 ± 3.6 ml min−1 1.73 m−2; P < 0.02) without altering body weight, effective renal plasma flow [131I]hippuran clearance), plasma renin activity (PRA), 24 h urinary volume or electrolyte excretion. 3. After discontinuation of sulindac, creatinine clearance returned to pretreatment values. 4. In five female patients, pretreatment urinary excretion of the 6-ketoprostaglandin F1α (6-keto-PGF1α), a stable breakdown product of prostacyclin (PGI2), was significantly reduced (P < 0.02) when compared with four healthy controls, whereas prostaglandin E2 (PGE2) was unchanged. Administration of sulindac did not significantly alter the excretion rate of PGE2 or 6-ketoPGF1α in this group of patients. 5. In chronic renal disease with moderate renal impairment, reduced renal prostacyclin synthesis may be an important predisposing factor to the renal toxicity associated with the use of nonsteroidal anti-inflammatory drugs (NSAID). Short term use of sulindac in therapeutic doses does not appear to influence the excretion of prostaglandins and produces only a minor reversible change in renal function; used cautiously it may have advantages over other NSAID in these patients.-
APA, Harvard, Vancouver, ISO, and other styles
10

Bilen Babić, Marijana, Petra Grubešić, Ivana Valković Antić, Renata Gržetić-Lenac, and Maja Merlak. "Nonsteroidal antiinflammatory drugs and treatment of cystoid macular edema." Medicina Fluminensis 55, no. 2 (June 1, 2019): 142–47. http://dx.doi.org/10.21860/medflum2019_218802.

Full text
Abstract:
Nonsteroidal antiinflammatory drugs (NSAIDs) have become a significant therapeutic adjunctive tool in the routine and complicated intraocular surgery. Topical NSAIDs prevent intraoperative miosis, reduce pain, postoperative inflammation and incidence of cystoid macular edema (CME). Although there is no established protocol for prophylaxis of pseudophakic CME, due to the relationship between proinflammatory prostaglandins and CME, using corticosteroids and NSAIDs could prevent CME. NSAIDs have a synergistic antiinflammatory effect with steroids, but can also be used alone when corticosteroid therapy could be harmful. Prospective clinical trials need to define treatment protocol for topical NSAIDs use, due to their powerful influence to prevent perioperative complications.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Prostaglandins Therapeutic use"

1

Hawkes, Joanna Susan. "N-3 fatty acids, eicosanoids and control of inflammation /." Title page, contents and summary only, 1993. http://web4.library.adelaide.edu.au/theses/09PH/09phh392.pdf.

Full text
Abstract:
Thesis (Ph. D.)--University of Adelaide, Dept. of Clinical and Experimental Pharmacology, and Rheumatology Unit, Royal Adelaide Hospital, 1994.
Errata slip inserted. Includes bibliographical references (leaves 178-199).
APA, Harvard, Vancouver, ISO, and other styles
2

"Prostanoid receptors on rat peritoneal mast cells." 1999. http://library.cuhk.edu.hk/record=b6073137.

Full text
Abstract:
by Chung Lap Chan.
"March 1999."
Thesis (Ph.D.)--Chinese University of Hong kong, 1999.
Includes bibliographical references (p. 270-307).
Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web.
Mode of access: World Wide Web.
Abstracts in English and Chinese.
APA, Harvard, Vancouver, ISO, and other styles
3

Khidhir, K. G., D. F. Woodward, N. P. Farjo, B. K. Farjo, E. S. Tang, J. W. Wang, S. M. Picksley, and V. A. Randall. "The prostamide-related glaucoma therapy, bimatoprost, offers a novel approach for treating scalp alopecias." 2013. http://hdl.handle.net/10454/6050.

Full text
Abstract:
Balding causes widespread psychological distress but is poorly controlled. The commonest treatment, minoxidil, was originally an antihypertensive drug that promoted unwanted hair. We hypothesized that another serendipitous discovery, increased eyelash growth side-effects of prostamide F(2alpha)-related eyedrops for glaucoma, may be relevant for scalp alopecias. Eyelash hairs and follicles are highly specialized and remain unaffected by androgens that inhibit scalp follicles and stimulate many others. Therefore, we investigated whether non-eyelash follicles could respond to bimatoprost, a prostamide F(2alpha) analog recently licensed for eyelash hypotrichosis. Bimatoprost, at pharmacologically selective concentrations, increased hair synthesis in scalp follicle organ culture and advanced mouse pelage hair regrowth in vivo compared to vehicle alone. A prostamide receptor antagonist blocked isolated follicle growth, confirming a direct, receptor-mediated mechanism within follicles; RT-PCR analysis identified 3 relevant receptor genes in scalp follicles in vivo. Receptors were located in the key follicle regulator, the dermal papilla, by analyzing individual follicular structures and immunohistochemistry. Thus, bimatoprost stimulates human scalp follicles in culture and rodent pelage follicles in vivo, mirroring eyelash behavior, and scalp follicles contain bimatoprost-sensitive prostamide receptors in vivo. This highlights a new follicular signaling system and confirms that bimatoprost offers a novel, low-risk therapeutic approach for scalp alopecias.
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Prostaglandins Therapeutic use"

1

H, Sinzinger, and Schrör Karsten, eds. Prostaglandins in clinical research: Proceedings of the 3rd International Symposium on Prostaglandins, held in Bad Ischl, Austria, September 16-20, 1986. New York: Liss, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bönner, Gerd. Prostacyclin and hypertension. Berlin: Springer-Verlag, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

B, Curtis-Prior P., ed. The eicosanoids. Chichester, England: John Wiley & Sons, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

European Congress on Prostaglandins in Reproduction (1st : 1988 : Vienna, Austria), ed. Prostaglandins for cervical ripening and/or induction of labour. [Wien, Austria]: Facultas Universitätsverlag, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

C, Diehm, Sinzinger H, and Rogatti W. 1947-, eds. Prostaglandin E₁: New aspects on pharmacology, metabolism, and clinical efficacy. Berlin: Springer-Verlag, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ryszard, Gryglewski, and Stock G, eds. Prostacyclin and its stable analogue, Iloprost. Berlin: Springer-Verlag, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

NATO Advanced Study Institute on Prostanoids and Drugs (1988 Erice, Italy). Prostanoids and drugs. New York: Plenum Press, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Z, Bito Laszlo, and Stjernschantz Johan, eds. The Ocular effects of prostaglandins and other eicosanoids. New York: A.R. Liss, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

T͡Sagareli, Zurab Georgievich. Funkt͡sionalʹnai͡a morfologii͡a aorty i serdechnoĭ mysht͡sy pri ėksperimentalʹnom ateroskleroze i posle vozdeĭstvii͡a prostaglandina Eı. Tbilisi: "Met͡sniereba", 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

F, Whitfield James, and Morley Paul Ph D, eds. Anabolic treatments for osteoporosis. Boca Raton: CRC Press, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources
You might also be interested in the extended bibliographies on the topic 'Prostaglandins Therapeutic use' for particular source types:
Journal articles Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography